The standard model of immune cell recruitment goes like this: blood vessel walls are coated in a sugar layer called the glycocalyx, made of heparan sulfate and other glycosaminoglycans. During inflammation, this layer is degraded — by enzymes like heparanase — which exposes adhesion molecules on the endothelial surface, allowing immune cells to stick, roll, and eventually cross the vessel wall into inflamed tissue. The glycocalyx is the gate; its degradation opens the gate; the immune cells walk through.
In this model, the barrier belongs to the wall. The immune cells are passengers: they detect the opening and respond. Everything about how we think about leukocyte extravasation — the rolling, the firm adhesion, the diapedesis — is structured around a barrier that belongs to the blood vessel, not to the cell trying to cross it.
Priestley et al. found that leukocytes carry their own heparan sulfate glycocalyx. The immune cells have a sugar coat. And they shed it — using their own heparanase — to exit the bloodstream during inflammation.
This is not just an additional detail. It shifts the locus of control. The immune cell isn't only responding to an opening in the vessel wall. It's actively removing its own barrier to enable its own passage. The gate doesn't just open from one side.
In a psoriasis-like skin inflammation model in mice, the researchers tested what happens when you protect the glycocalyx from cleavage using a heparan sulfate mimetic. The drug worked: fewer immune cells accumulated in the inflamed skin. By the standard model, this should reduce inflammation. Fewer soldiers at the site means less damage.
It didn't. Clinical signs of inflammation worsened. The skin got more inflamed, not less, despite having fewer immune cells present.
The explanation is differential: the glycocalyx shedding mechanism isn't used equally by all immune cell types. Regulatory T cells — the immunological peacekeepers whose job is to suppress excessive inflammation — were disproportionately blocked by the treatment. The heparan sulfate mimetic protected the sugar coat on all leukocytes, but the ones that most needed to shed it to reach the tissue were the ones responsible for calming the inflammation down. By blocking everyone's passage equally, the drug preferentially blocked the cells whose arrival would have resolved the crisis.
This is a specific and experimentally verified instance of a general pattern: interventions that treat the immune system as monolithic make things worse because the immune system is not monolithic. The inflammatory cells and the regulatory cells use overlapping but not identical recruitment mechanisms. A blanket intervention hits both — but the damage from losing regulators outweighs the benefit from losing effectors.
What makes this finding structurally interesting is that the field wasn't wrong about the endothelial glycocalyx. It was right. The vessel wall barrier is real and important. The error was in assuming completeness — that because the endothelial glycocalyx was a known and characterized barrier, the relevant barriers had been identified. The leukocyte glycocalyx was sitting on the surface of the cells that immunologists spend their careers studying, and it was invisible because the concept of “barrier” was assigned to the vessel, not the traveler.
The paradox at the end — blocking the mechanism worsens the disease — is the kind of result that forces model revision. In the two-barrier model (endothelial glycocalyx plus blood-brain barrier, or endothelial glycocalyx plus tissue architecture), blocking glycocalyx degradation should straightforwardly reduce immune cell infiltration and therefore reduce inflammation. In the three-barrier model (endothelial glycocalyx plus leukocyte glycocalyx plus tissue architecture), the prediction changes: because different cell types depend differently on their own glycocalyx for extravasation, blanket inhibition of shedding is not an anti-inflammatory intervention. It's a selective depletion of the cells you most need. The difference between the two models isn't academic. It's the difference between a drug that works and a drug that kills.